NRx targets 2026 KETAFREE approval and outlines SPARC-TMS trial in 400 patients backed by military funding

NRx Pharmaceuticals announced that it is pursuing the SPARC-TMS clinical trial, aiming for KETAFREE approval in 2026, with military funding support.

AI CATALYST SCORE75 / 100Score computed by Sentinel V12

REFERENCE PRICENot measuredReference entry price at analysis time

ANALYSIS HISTORY

NRXP Analysis History (Last 30 Days)

Diagnosed At	Ticker	AI Score	Tier
2026-09-30 11:26:58	NRXP	78	S-Class	View Report →
2026-08-18 15:14:58	NRXP	75	Mid	View Report →
2026-08-17 11:16:22	NRXP	50	Row	View Report →

RELATED REPORTS

Diagnosed At	Ticker	AI Score	Tier
2026-10-03 03:59:23	NTRA	30	Row	View Report →
2026-10-03 03:59:08	NTRA	35	Row	View Report →
2026-10-02 21:48:45	NVO	40	Row	View Report →
2026-10-02 20:31:36	LLY	65	Mid	View Report →
2026-10-02 19:46:11	BIIB	70	Mid	View Report →
2026-10-02 16:13:52	QGEN	78	S-Class	View Report →
2026-10-02 15:45:52	DSGN	70	Mid	View Report →
2026-10-02 15:25:39	BMRN	50	Mid	View Report →
2026-10-02 15:18:46	LLY	75	Mid	View Report →
2026-10-02 14:17:50	CAPR	40	Row	View Report →
2026-10-02 14:12:58	FHTX	45	Mid	View Report →
2026-10-02 07:21:00	ARIS	75	S-Class	View Report →
2026-10-02 06:47:26	SMMT	75	S-Class	View Report →
2026-10-02 00:40:43	MRNA	62	Mid	View Report →
2026-10-01 22:13:48	UTHR	35	Row	View Report →
2026-10-01 21:43:30	SGMT	45	Mid	View Report →
2026-10-01 15:27:33	ABBV	65	Mid	View Report →
2026-10-01 14:58:01	WVE	82	S-Class	View Report →
2026-10-01 12:07:59	FHTX	50	Mid	View Report →
2026-10-01 11:42:00	LLY	78	Mid	View Report →
2026-09-30 21:51:43	MLTX	80	Mid	View Report →
2026-09-30 21:08:17	RPRX	30	Row	View Report →
2026-09-30 20:39:58	UTHR	85	S-Class	View Report →
2026-09-30 17:53:41	NUVB	75	Mid	View Report →
2026-09-30 16:57:50	ABUS	75	Mid	View Report →
2026-09-30 15:44:25	ACHV	75	S-Class	View Report →
2026-09-30 14:51:53	CNTB	80	S-Class	View Report →
2026-09-30 14:48:10	LLY	70	Mid	View Report →
2026-09-30 14:19:45	LLY	78	Mid	View Report →
2026-09-30 13:34:55	MRK	65	Mid	View Report →